Citation Impact
Citing Papers
Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours
2003
The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages
2000 StandoutNobel
Hypoxia — a key regulatory factor in tumour growth
2002 Standout
Uptake and retention of nitroimidazole-carboranes designed for boron neutron capture therapy in experimental murine tumours: 11 detection by B magnetic resonance spectroscopy
1996
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
Applicability of animal tumor data to cancer therapy in humans
1988
Targeting hypoxia in cancer therapy
2011 Standout
The third dimension bridges the gap between cell culture and live tissue
2007 Standout
The role of porphyrin chemistry in tumor imaging and photodynamic therapy
2010 Standout
Cisplatin: mode of cytotoxic action and molecular basis of resistance
2003 Standout
Design of anticancer prodrugs for reductive activation
2008
Drug penetration in solid tumours
2006 Standout
Radiation therapy alone or combined with misonidazole in the treatment of locally advanced non-oat cell lung cancer: Report of an rtog prospective randomized trial
1989
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Radiosensitization by 2-nitroimidazole nucleoside analog rp-170: Radiosensitizing effects under both intravenous and oral administration
1992 StandoutNobel
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Engineering the perfect (bacterial) cancer therapy
2010 Standout
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)
1993
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
1997 Standout
Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin
1993
Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-trihydroxy-2′-butoxy)methyl-2-nitroimidazole(RP-343)
1993 StandoutNobel
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Radiosensitization by a new nucleoside analogue: 1-[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl-2-nitroimidazole (RP-170)
1989 StandoutNobel
The experimental development of bioreductive drugs and their role in cancer therapy
1993
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
2006 Standout
Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 α-Subunit (HIF-1α)
1998 StandoutNobel
Inhibition of N‐methyl‐N′'‐nitro‐n‐nitrosoguanidine‐induced methotrexate and adriamycin resistance in CHO cells by adeno‐associated virus type 2
1990 StandoutNobel
Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours
2002
Combining bioreductive drugs and radiation for the treatment of solid tumors
2003
The pathobiology of mucositis
2004 Standout
Pharmacokinetics of 2-nitroimidazole Hypoxic Cell Radiosensitizers in Rodent Peripheral Nervous Tissue
1990
Bioreductive drugs for cancer therapy: The search for tumor specificity
1994
Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo
1992
Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069
1995
Targeting gene expression to hypoxic tumor cells
1997 StandoutNobel
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
1991 Standout
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
1994 Standout
Synthesis and radioiodination of a nido-1,2-carboranyl derivative of 2-nitroimidazole
1994
SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
1993
Targeting tumors with hypoxia-activated cytotoxins
2007
Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin
1988
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Oncogenic alterations of metabolism
1999 StandoutNobel
Studies of human tumors by MRS: A review
1992
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
1998 Standout
Selective down-regulation of human papillomavirus transcription by 2-deoxyglucose
1998 StandoutNobel
Up-regulation of Apoptosis Inhibitory Protein IAP-2 by Hypoxia
2001 StandoutNobel
The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508
1982
The optimum time for irradiation relative to tumour concentration of hypoxic cell sensitizers
1980
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Partition Coefficient as a Guide to the Development of Radiosensitizers Which Are Less Toxic Than Misonidazole
1980
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
2000 StandoutNobel
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient
1987
HYPOXIC CELL SENSITISERS IN RADIOTHERAPY
1976
Radiosensitizers of hypoxic cells in solid tumours
1976
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.
1992 StandoutNobel
Three A's of repopulation during fractionated irradiation of squamous epithelia: Asymmetry loss, Acceleration of stem-cell divisions and Abortive divisions
1997
Hypoxia-specific cytotoxins in cancer therapy
1996
Metal Complexes as Photo- and Radiosensitizers
1999
13C labeling in studies of metabolic regulation
1988
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
1998
Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics
2006 StandoutNobel
A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069
1986
Selective Radiosensitization of the Hypoxic Cells of Mouse Tumors with the Nitroimidazoles Metronidazole and Ro 7-0582
1975
Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.
1983
Hypoxia-inducible Factor-1 Mediates Transcriptional Activation of the Heme Oxygenase-1 Gene in Response to Hypoxia
1997 StandoutNobel
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics
2002 StandoutScience
Clinical trials of radiosensitizers: What should we expect?
1984
Are cancer cells acidic?
1991
Stereospecific assignment of the methyl 1H NMR lines of valine and leucine in polypeptides by nonrandom 13C labelling
1989 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Cell and Environment Interactions in Tumor Microregions: The Multicell Spheroid Model
1988 StandoutScience
Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses
1990
The pathogenesis of cancer metastasis
1980 StandoutNature
Microenvironment-induced cancer metastasis
2000
The multicellular spheroid system as a tumor model for studies of radiation sensitizers
1980
Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers
1982
Chemistry of Biologically Important Synthetic Organoselenium Compounds
2001 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
The Chemistry of Neutron Capture Therapy
1998 Standout
The Biology of Cancer Invasion and Metastasis
1978
Potentiation of chemotherapy by hypoxic cell radiation sensitizers—A review
1982
Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy
1981
Therapeutic advantage in preoperative single‐dose radiation combined with conservative and radical surgery in different‐size murine fibrosarcomas
1985
Tumor hypoxia: its impact on cancer therapy
1987
Chemodynamic Therapy: Tumour Microenvironment‐Mediated Fenton and Fenton‐like Reactions
2018 Standout
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
1999
HIF-1 and human disease: one highly involved factor
2000 StandoutNobel
Development of drug resistance in a murine mammary tumour
1985
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342
1985
Radiosensitizers: A conference preview
1984
Electron-Affinic SensitizationVII. A Correlation between Structures, One-Electron Reduction Potentials, and Efficiencies of Nitroimidazoles as Hypoxic Cell Radiosensitizers
2012
Interactions among clonal subpopulations affect stability of the metastatic phenotype in polyclonal populations of B16 melanoma cells.
1981
Intermittent blood flow in a murine tumor: radiobiological effects.
1987
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity
2006 StandoutNobel
Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites.
1986
The Pharmacokinetics and Tumor and Neural Tissue Penetrating Properties of SR-2508 and SR-2555 in the Dog-Hydrophilic Radiosensitizers Potentially Less Toxic than Misonidazole
1980
Works of P.W. Sheldon being referenced
RSU 1069, a nitroimidazole containing an aziridine group
1986
The Interaction Between Radiation and Complexes ofCis-Pt(II) and Rh(II): Studies at the Molecular and Cellular Level
1985
Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds
1982
Optimum fractionation in X-ray treatment of C3H mouse mammary tumours
1974
Induction of hypoxia in normal and malignant tissues by changing the oxygen affinity of hemoglobin—Implications for theraphy
1986
Demonstration of radiosensitization of hypoxic cells in solid tumours by metronidazole
1974
5-Flourouracil metabolism monitored in vivo by 19F NMR
1984
Radioprotection by Pentobarbitone Sodium of a Murine Tumourin Vivo
1977
Evaluation of novel radiation sensitizers in vitro and in vivo
1982
The Effect of Anesthetics on the Radiosensitivity of a Murine Tumor
1979
Radiosensitizationin Vivo: A Study with an Homologous Series of 2-nitroimidazoles
1983
Skin Reactions in Mice after Multifraction X-irradiation
1974
Radiosensitization by Misonidazole (Ro 07-0582) The Importance of Timing and Tumor Concentration of Sensitizer
1978
The Incidence of Lung Metastases in C3h Mice after Treatment of Implanted Solid Tumours with X-rays or Surgery
1974
The Effect of Irradiating a Transplanted Solid Sarcoma on the Subsequent Development of Metastases
1974
The effect of radiation on tumour growth delay, cell survival and cure of the animal using a single tumour system
1977
Radiosensitization of C3H Mouse Mammary Tumours by a 2-Nitroimidazole Drug
1974
Modest radiosensitization of solid tumours in C3H mice by the hypoxic cell radiosensitizer NDPP
1975
Radiation sensitization and chemopotentiation: Rsu 1069, a compound more efficient than misonidazole in vitro and in vivo
1984
Potentiation in vivo of melphalan activity by nitroimidazole compounds
1982
The effect of recovery from potentially lethal damage on the determination of repair and repopulation in a murine tumour
1985
Influence ofin vitroassay conditions on the assessment of radiobiological parameters of the MT tumour
1980
Radiosensitization of C3H mouse mammary tumours using fractionated doses of X rays with the drug Ro-07–0582
1976
Radiosensitization by misonidazole (Ro-07-0582) of fractionated X-rays in a murine tumour.
1978
Further investigations of the effects of the hypoxic-cell radiosensitizer, Ro-07-0582, on local control of a mouse tumour
1977
The Effect of Pentobarbital Anaesthesia on the Radiosensitivity of Four Mouse Tumours
1979
Optimum fractionation of the C3H mouse mammary carcinoma using X-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons
1976
Biological Properties and Response to X-rays of First-generation Transplants of Spontaneous Mammary Carcinomas in C3H Mice
1975
Analogues of RSU-1069: Radiosensitization and toxicity in vitro and in vivo
1986
RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivo
1984
The Effect of Irradiating a Transplanted Murine Lymphosarcoma on the Subsequent Development of Metastases
1973